Literature DB >> 29304575

Pathologic Cuticular Changes of Winter Impoundment Shell Disease Preceding and During Intermolt in the American Lobster, Homarus americanus.

R M Smolowitz, R A Bullis, D A Abt.   

Abstract

Cuticular lesions from twenty-four market sized lobsters (Homarus americanus) with winter impoundment shell disease were examined. Histological descriptions of cuticular lesions were correlated with the substage of molt for each lobster, because cuticle components and inflammatory mechanisms vary in each. A lesion severity grading system was developed and applied to four specific substages of the five-stage (A-E) molting cycle. Lesions present in substage C4, in which the membranous layer is deposited, and D0 (passive premolt) were divided into five grades, ranging from mild erosions (Grade I) to severe ulceration (Grade V) of the cuticle. Cuticular lesions from lobsters in C4/D0 were compared with cuticular lesions from lobsters in substages C2/C3. Defensive mechanisms exhibited by animals in all substages were epicuticle deposition, melanization, inflammatory cell infiltration, and pseudomembrane formation. In addition, animals in C4 and D0 showed proliferation of the membranous layer in affected foci. The lesion grading scheme presented in this paper can be used to describe and compare both inter- and intraspecies crustacean shell lesions.

Entities:  

Year:  1992        PMID: 29304575     DOI: 10.2307/1542411

Source DB:  PubMed          Journal:  Biol Bull        ISSN: 0006-3185            Impact factor:   1.818


  2 in total

1.  Effect of extracellular products of Pseudoalteromonas atlantica on the edible crab Cancer pagurus.

Authors:  Carolina Costa-Ramos; Andrew F Rowley
Journal:  Appl Environ Microbiol       Date:  2004-02       Impact factor: 4.792

2.  Increased disease calls for a cost-benefits review of marine reserves.

Authors:  Emma C Wootton; Andrew P Woolmer; Claire L Vogan; Edward C Pope; Kristina M Hamilton; Andrew F Rowley
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.